SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Kirk's Market Thoughts -- Ignore unavailable to you. Want to Upgrade?


To: robert b furman who wrote (9336)4/20/2020 11:12:55 AM
From: Kirk ©1 Recommendation

Recommended By
Sun Tzu

  Read Replies (6) | Respond to of 26760
 
This study is funny.... they could not enlist enough volunteers in Australia.

It is also interesting that they had to stop one study of chloroquine to treat COVID-19 because too many died of heart issues...

I've read people are boozing it up at home and that could be detrimental to their health for reasons beyond alcohol is a depressant and highly addictive to about 10% of those who use it.

berkeleywellness.com

Reducing your intake of alcohol might improve atrial fibrillation (AFib), a common type of irregular heartbeat, according to an Australian study in The New England Journal of Medicine. It found that moderate to heavy drinkers with AFib—a leading cause of stroke—who lowered their alcohol intake had fewer episodes of arrhythmias (abnormal heart rhythms) when measured against those who didn’t change their drinking habits.
...
It's worth noting that the original length of the clinical trial was slated to be one year. However, the researchers couldn’t recruit enough participants to commit to abstinence for that long, so the trial length was shortened to six months. Longer trials are needed to see whether the positive effects persist.

and

Trial of chloroquine to treat COVID-19 stopped early due to heart complications
livescience.com
However, after enrolling just 81 patients, the researchers saw some concerning signs. Within a few days of starting the treatment, more patients in the high dose group experienced heart rhythm problems than did those in the low dose group. And two patients in the high dose group developed a fast, abnormal heart rate known as ventricular tachychardia before they died.